Economic evaluation of Restrictive Vs. Liberal Transfusion Strategy Following Acute Myocardial Infarction (REALITY): trial-based cost effectiveness and cost utility analyses.
Isabelle Durand ZaleskiGregory DucrocqMaroua MimouniJerome FrenkielCristina Avendano-SoláJose R Gonzalez-JuanateyEmile FerrariGilles LemesleEtienne PuymiratLaurence BerardMarine CachanadoJoan Albert ArnaizManuel Martínez-SellésJohanne SilvainAlbert Ariza SoléGonzalo CalvoTabassome SimonSandra PacoElodie DrouetHelene AbergelAlexandra RousseauTabassome SimonPhillippe Gabriel Stegnull nullPublished in: European heart journal. Quality of care & clinical outcomes (2022)
In patients with acute myocardial infarction and anemia, the restrictive transfusion strategy was dominant (cost-saving and outcome-improving) at 30 days. At 1 year, the restrictive strategy remained cost-saving but clinical noninferiority on MACE was no longer maintained. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT02648113.